Ecnoglutide
/ Biased GLP-1 receptor agonist (functional selectivity for cAMP over beta-arrestin)ALIAS · XW003 · Ecnoglutide
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 2. Phase 2 trials in type 2 diabetes and obesity in Chinese populations (Sciwind Biosciences sponsor). Phase 3 trials in China have begun. Not approved by any regulator as of the cutoff.
Ecnoglutide is a synthetic GLP-1 receptor agonist engineered for functional selectivity (biased agonism): preferential coupling to the canonical Gs/cAMP signalling pathway with reduced beta-arrestin recruitment relative to balanced GLP-1 receptor agonists. The biased pharmacology is hypothesised to retain insulinotropic and weight-loss efficacy while reducing class adverse events (notably nausea and gastrointestinal effects) thought to be mediated in part by beta-arrestin signalling. The molecule is acylated for albumin binding to support once-weekly subcutaneous dosing.
Tier 2. Phase 2 trials in Chinese participants with type 2 diabetes and with obesity have been reported by the sponsor and at scientific meetings; peer-reviewed publication of full Phase 2 results is limited as of the cutoff. Phase 3 trials in China are in progress.
Class GLP-1 receptor agonist adverse events (nausea, decreased appetite, vomiting) are reported at frequencies the sponsor has characterised as comparable or slightly lower than balanced GLP-1 receptor agonists; independent verification through published Phase 3 data is pending. Pancreatitis and C-cell tumour signals from the class apply.
Regulatory status
- FDA status:
- Not FDA-approved
Biased agonism at the GLP-1 receptor is a contested pharmacological hypothesis: whether reduced beta-arrestin recruitment translates to clinically meaningful adverse-event reduction at matched efficacy is an open empirical question that requires head-to-head Phase 3 evidence against established GLP-1 receptor agonists. The Sciwind program is one of several biased GLP-1 receptor agonists in development. Vendor research-grade 'ecnoglutide' is unlikely to be pharmaceutically equivalent to clinical-grade material.